Brainsway (NASDAQ:BWAY) Trading Down 4.4% - What's Next?

Key Points

• Brainsway shares fell about 4.4% on Monday to $12.97 (intraday low $13.31) on light trading of ~50,245 shares, roughly a 76% drop versus the 206,300 average; the 50‑ and 200‑day moving averages are $12.73 and $10.14.
• Analysts carry a consensus "Buy" rating with a $15.00 consensus target after recent activity that included upgrades from Wall Street Zen and Zacks and HC Wainwright cutting its target to $15 from $30.
• Brainsway beat the latest quarter's estimates (EPS $0.14 vs. $0.11 expected; revenue $14.55M vs. $14.02M), while the company trades at a market cap of about $502M and a P/E around 50, reflecting expectations for its Deep TMS neuromodulation platform.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report)'s stock price was down 4.4% on Monday . The company traded as low as $13.31 and last traded at $12.97. Approximately 50,245 shares were traded during trading, a decline of 76% from the average daily volume of 206,300 shares. The stock had previously closed at $13.57.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BWAY shares. Wall Street Zen raised Brainsway from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. HC Wainwright dropped their target price on shares of Brainsway from $30.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday, March 12th. Northland Securities set a $15.00 price target on Brainsway in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Brainsway from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 24th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Brainsway in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Brainsway currently has a consensus rating of "Buy" and a consensus target price of $15.00.

Brainsway Trading Down 7.6%

The firm's fifty day moving average price is $12.73 and its 200-day moving average price is $10.14. The company has a market cap of $501.82 million, a P/E ratio of 50.16 and a beta of 1.10.

Brainsway (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.03. Brainsway had a net margin of 14.62% and a return on equity of 11.10%. The company had revenue of $14.55 million during the quarter, compared to analysts' expectations of $14.02 million. As a group, research analysts forecast that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of Brainsway

A number of institutional investors and hedge funds have recently modified their holdings of BWAY. Y.D. More Investments Ltd lifted its stake in Brainsway by 559.8% in the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company's stock valued at $2,187,000 after buying an additional 97,537 shares in the last quarter. Zuckerman Investment Group LLC grew its stake in shares of Brainsway by 5.3% during the 3rd quarter. Zuckerman Investment Group LLC now owns 40,000 shares of the company's stock worth $603,000 after acquiring an additional 2,000 shares in the last quarter. Essex Investment Management Co. LLC raised its holdings in shares of Brainsway by 3.2% in the third quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company's stock valued at $4,682,000 after purchasing an additional 9,744 shares during the last quarter. Huntleigh Advisors Inc. lifted its position in shares of Brainsway by 6.3% in the third quarter. Huntleigh Advisors Inc. now owns 82,265 shares of the company's stock worth $1,240,000 after purchasing an additional 4,849 shares in the last quarter. Finally, Eagle Global Advisors LLC lifted its position in shares of Brainsway by 19.3% in the third quarter. Eagle Global Advisors LLC now owns 74,326 shares of the company's stock worth $1,120,000 after purchasing an additional 12,000 shares in the last quarter. 30.11% of the stock is owned by institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.